Catheter Precision, Inc. filings document material events, operating results, shareholder votes, capital-structure matters, and governance disclosures for a NYSE American-listed company. The records include 8-K reports on financial results and business updates tied to the company’s electrophysiology products, including VIVO and LockeT, as well as strategic expansion activity.
VTAK’s proxy and current-report filings also cover stockholder approval matters, common-stock issuance proposals, convertible preferred stock series, promissory note amendments, royalty-right exchanges, related-party transaction disclosures, and other material agreements. These filings frame the company’s public reporting around medical device commercialization, financing arrangements, and corporate governance.
Catheter Precision, Inc. extended the maturities of several 8% Short Term Promissory Notes held by entities associated with its executive chair and CEO, David A. Jenkins. On December 31, 2025, the company entered into Second Amendments to these notes, moving their maturity dates from January 31, 2026 to January 31, 2028 for a $500,000 note held by Jenkins Family Charitable Institute and to January 31, 2029 for notes with principal amounts of $500,000, $150,000, $250,000 and $100,000 held by Mr. Jenkins and FatBoy Capital, L.P.
The filing highlights that Mr. Jenkins is the managing member of the general partner of FatBoy Capital and the settlor of the Jenkins Family Charitable Institute, and that he and his affiliates also hold stock options and rights to receive 11.77% royalties on net sales of the LockeT device. The amendments are treated as a material definitive agreement and a direct financial obligation for the company.
Catheter Precision, Inc. director James J. Caruso reported a small equity transaction in the company’s stock. On 12/05/2025, he acquired 41 shares of common stock at a price of $0 per share in a transaction coded “C,” indicating a conversion. Following this transaction, he directly beneficially owned 50 shares of common stock.
The filing also shows activity in Series X Convertible Preferred Stock, with a conversion price of $0. On the same date, 7.932 shares of this preferred stock were involved in a transaction coded “C,” with no common shares shown as underlying afterward and 0 derivative securities beneficially owned. The accompanying note explains that the Series X Convertible Preferred Stock has no expiration date.
Catheter Precision, Inc. reported an insider stock transaction by its Chairman and CEO, David A. Jenkins. On 12/05/2025, Jenkins converted shares of Series X Convertible Preferred Stock into common stock at a stated price of $0 per share. Following these conversions, he directly held 13,799 common shares, with an additional 34,579 shares held indirectly through a partnership and 109 shares held indirectly through a charitable remainder unitrust. The filing notes that the preferred stock has no expiration date and that some of the indirectly held shares are controlled via entities managed by Jenkins or his spouse, clarifying the structure of his beneficial ownership.
Catheter Precision, Inc. reported that it has given notice to terminate its At-Market-Offering Agreement with Ladenburg Thalmann & Co. Inc., which supported its at-the-market equity offering program. The termination is scheduled to be effective on November 24, 2025.
The program allowed the company to offer and sell shares of common stock with an aggregate offering price of up to $4.3 million. Before issuing the termination notice, Catheter Precision sold approximately $4.0 million of common stock under this program, and it will not owe any termination penalties.
Catheter Precision, Inc. (VTAK) reported that it furnished a press release announcing financial results for the three and nine months ended September 30, 2025. The company provided this update under Item 2.02 of the Exchange Act.
The press release is included as Exhibit 99.1 and, as stated, the information is being furnished and not deemed filed under Section 18. VTAK’s common stock trades on NYSE American.
Catheter Precision, Inc. reported Q3 2025 results showing small but growing sales and ongoing losses, alongside a going concern warning. Revenue was $226,000 for the quarter (vs. $96,000 a year ago) and $581,000 for the nine months (vs. $271,000). Net loss attributable to the company was $2.251 million in Q3 and $11.405 million year to date.
Cash and cash equivalents were $1.075 million as of September 30, 2025, with a working capital deficit of $2.9 million and accumulated deficit of $303.8 million. Total liabilities were $19.0 million, including royalties payable due to related parties of $10.743 million. Management states there is substantial doubt about the ability to continue as a going concern.
To fund operations, the company completed a private placement on May 12, 2025 collecting $1.5 million in cash plus QHSLab notes, and sold 868,582 shares under an ATM launched May 19, 2025 for gross proceeds of $4.0 million. A 1‑for‑19 reverse stock split became effective on August 15, 2025. Shares outstanding were 1,668,375 as of November 7, 2025.
Catheter Precision (VTAK) reported the results of a stockholder Special Meeting held on October 10, 2025. Of the 1,487,266 shares outstanding as of September 10, 2025 (the record date), 641,616 shares were represented in person or by proxy, constituting approximately 43.1% of shares entitled to vote.
Stockholders considered three proposals. Reported vote totals were: Proposal 1 — 497,162 for, 133,882 against, 10,571 abstentions; Proposal 2 — 610,134 for, 16,778 against, 14,703 abstentions; Proposal 3 — 514,362 for, 120,394 against, 6,860 abstentions.
Catheter Precision, Inc. is calling a special stockholder meeting on October 10, 2025 to vote on three items. The main proposal would amend its charter to increase authorized common shares from 60,000,000 to 500,000,000, giving the company room to issue large amounts of stock or stock-linked securities in future financings. The company states it will be unable to fund operations and pay obligations beyond January 2026 unless a financing is completed.
Stockholders are also being asked to ratify WithumSmith+Brown, PC as independent auditor for the year ending December 31, 2026, and to approve the ability to adjourn the meeting if there are not enough votes for the other proposals. The proxy describes a complex capital structure, including Series X and Series B preferred stock and 1,078,895 outstanding warrants with various exercise prices, ownership limits, and change‑of‑control protections.
Catheter Precision, Inc. is asking stockholders at an October 10, 2025 virtual special meeting to approve a major increase in authorized common stock, from 60,000,000 to 500,000,000 shares. The company currently has 1,487,266 common shares outstanding as of September 10, 2025.
The board explains that it needs far more authorized shares to pursue additional financings to fund ongoing operations, stating it will be unable to fund operations and pay obligations beyond January 2026 unless a financing is completed. The proxy also asks stockholders to ratify WithumSmith+Brown, PC as auditor for 2026 and to approve a proposal allowing adjournment of the meeting if needed to secure sufficient votes.
Catheter Precision filed an 8-K to attach a legal opinion supporting its Form S-3 prospectus supplement and to announce that its LockeT surgical vessel closing device received regulatory approval in Great Britain. The press release highlights potential benefits of LockeT for patient comfort, faster recovery and increased clinical throughput, but also contains extensive forward-looking cautionary language. The company discloses material weaknesses in internal control, a history of losses, the need to raise additional funds to continue operations, and multiple operational and market risks including competition, reimbursement, supply-chain and regulatory challenges.